Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability